{"id": "63f57d9b33942b094c000004_0", "question": "Which amino acid in implicated in the Blue diaper syndrome?", "context": "Blue diaper syndrome (BDS) (Online Mendelian Inheritance in Man number 211000) is an extremely rare disorder that was first described in 1964. The characteristic finding is a bluish discoloration of urine spots in the diapers of affected infants. Additional clinical features of the first described patients included diarrhea, inadequate weight gain, hypercalcemia, and nephrocalcinosis. An intestinal defect of tryptophan absorption was postulated as the underlying pathology.", "label": "yes"}
{"id": "63f57d9b33942b094c000004_1", "question": "Which amino acid in implicated in the Blue diaper syndrome?", "context": "We describe the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan. ", "label": "yes"}
{"id": "6450ec0c57b1c7a31500008f_0", "question": "What is the cause of Friedreich's Ataxia (FA)?", "context": "Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin protein.", "label": "yes"}
{"id": "644ef46557b1c7a315000083_0", "question": "What are positive cell-cycle regulators that can cause cancer when mutated called?", "context": "Oncogenes are gain-of-function mutations of normal regulatory genes or proto-oncogenes. Originally discovered in retroviruses initiating a variety of animal and avian cancers, oncogenes are believed to be important contributors to human carcinogenesis. Proto-oncogenes are altered by point mutation, amplification or rearrangement.", "label": "yes"}
{"id": "6432fdd857b1c7a315000020_0", "question": "What is the inheritance pattern of hereditary angioedema?", "context": "Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes.", "label": "yes"}
{"id": "6450ede757b1c7a315000090_0", "question": "What is usually the onset age of Friedreich's Ataxia?", "context": "Friedreich's ataxia is classically considered a disease with onset in the first or second decade.", "label": "yes"}
{"id": "63f03d58f36125a42600001f_0", "question": "What disease was the topic of the World Hip Trauma Evaluation (WHiTE) trial?", "context": "Cost-utility analysis of cemented hemiarthroplasty versus hydroxyapatite-coated uncemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures : the World Hip Trauma Evaluation 5 (WHiTE 5) trial.", "label": "yes"}
{"id": "63f03d58f36125a42600001f_1", "question": "What disease was the topic of the World Hip Trauma Evaluation (WHiTE) trial?", "context": "A randomized clinical trial of low dose single antibiotic-loaded cement versus high dose dual antibiotic-loaded cement in patients receiving a hip hemiarthroplasty after fracture: A protocol for the WHiTE 8 COPAL study.", "label": "yes"}
{"id": "63f03d58f36125a42600001f_2", "question": "What disease was the topic of the World Hip Trauma Evaluation (WHiTE) trial?", "context": "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI - An Abridged Protocol.", "label": "yes"}
{"id": "63f03d58f36125a42600001f_3", "question": "What disease was the topic of the World Hip Trauma Evaluation (WHiTE) trial?", "context": "METHODS AND ANALYSIS: The World Hip Trauma Evaluation (WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip fracture. ", "label": "yes"}
{"id": "644008a657b1c7a31500003f_0", "question": "What is the alternative name of RTA 408?", "context": "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics. ", "label": "yes"}
{"id": "644640de57b1c7a31500006b_0", "question": "What is the cause of Spinal Muscular Atrophy (SMA)?", "context": "SMA is a monogenic pathology that originates from the loss of the SMN1 gene in most cases or mutations in rare cases. ", "label": "yes"}
{"id": "644640de57b1c7a31500006b_1", "question": "What is the cause of Spinal Muscular Atrophy (SMA)?", "context": "Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder caused by defects in the survival motor neuron 1 (SMN1) gene.", "label": "yes"}
{"id": "644640de57b1c7a31500006b_2", "question": "What is the cause of Spinal Muscular Atrophy (SMA)?", "context": "Loss or deletion of survival motor neuron 1 gene (SMN1) is causative for a severe and devastating neuromuscular disease, Spinal Muscular Atrophy (SMA). ", "label": "yes"}
{"id": "644640de57b1c7a31500006b_3", "question": "What is the cause of Spinal Muscular Atrophy (SMA)?", "context": "Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1 (encoding survival motor neuron protein (SMN)). Reduced expression of SMN leads to loss of \u03b1-motor neurons, severe muscle weakness and often early death.", "label": "yes"}
{"id": "64403a5857b1c7a31500004c_0", "question": "What was the phase of the clinical trial PEACHTREE?", "context": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.", "label": "yes"}
{"id": "64402bb057b1c7a315000043_0", "question": "In what type of clinical trial has RT001 been evaluated against Friedreich's ataxia?", "context": "Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.", "label": "yes"}
{"id": "64402bb057b1c7a315000043_1", "question": "In what type of clinical trial has RT001 been evaluated against Friedreich's ataxia?", "context": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). ", "label": "yes"}
{"id": "63eef8d6f36125a42600000f_0", "question": "L9LS was developed for which disease?", "context": "METHODS: We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection in healthy adults who had never had malaria or received a vaccine for malaria.", "label": "yes"}
{"id": "63eef8d6f36125a42600000f_1", "question": "L9LS was developed for which disease?", "context": "CONCLUSIONS: In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns.", "label": "yes"}
{"id": "63eef8d6f36125a42600000f_2", "question": "L9LS was developed for which disease?", "context": "L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1 ", "label": "yes"}
{"id": "64121f44201352f04a000037_0", "question": "What does PROTACs stand for?", "context": "Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.", "label": "yes"}
{"id": "64121f44201352f04a000037_1", "question": "What does PROTACs stand for?", "context": "The emerging technology proteolysis targeting chimera (PROTAC) could be an alternative strategy to overcome these problems. ", "label": "yes"}
{"id": "6451029f57b1c7a315000094_0", "question": "What is the incidence of Leigh syndrome?", "context": "Leigh syndrome (LS), or subacute necrotizing encephalomyelopathy, is the most common childhood mitochondrial encephalopathy, accounting for more than 50% of cases in this age group. Its estimated incidence is 1:40,000 - 1:77,000 liveborn infants a year.", "label": "yes"}
{"id": "6432f5f257b1c7a31500001c_0", "question": "What does Zanubrutinib inhibit?", "context": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy. B", "label": "yes"}
{"id": "6432f5f257b1c7a31500001c_1", "question": "What does Zanubrutinib inhibit?", "context": "To reduce these side effects, zanubrutinib, a next-generation BTK inhibitor, was designed to block BTK more specifically than ibrutinib.", "label": "yes"}
{"id": "6440420857b1c7a315000050_0", "question": "What is Apretude used for?", "context": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.", "label": "yes"}
{"id": "6440420857b1c7a315000050_1", "question": "What is Apretude used for?", "context": "Cabotegravir extended-release (ER) injectable suspension (Apretude\u2122) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP). ", "label": "yes"}
{"id": "6440420857b1c7a315000050_2", "question": "What is Apretude used for?", "context": "Cabotegravir ER injectable suspension is indicated in the USA for PrEP to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing \u2265 35 kg who have a negative HIV-1 test prior to initiation.", "label": "yes"}
{"id": "6440420857b1c7a315000050_3", "question": "What is Apretude used for?", "context": "With its convenient, less-frequent dosing schedule and its long-acting formulation enabling intramuscular administration, cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral PrEP.", "label": "yes"}
{"id": "63eef4f5f36125a42600000b_0", "question": "What disease is treated with Ublituximab?", "context": "Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.", "label": "yes"}
{"id": "63eef4f5f36125a42600000b_1", "question": "What disease is treated with Ublituximab?", "context": "Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS).", "label": "yes"}
{"id": "63eef4f5f36125a42600000b_2", "question": "What disease is treated with Ublituximab?", "context": " In the second part of the review, we summarize medications that have targeted B cells in patients with MS and their current position in the therapeutic armamentarium based on clinical trials and real-world data. Covered therapeutic strategies include the targeting of surface molecules such as CD20 (rituximab, ocrelizumab, ofatumumab, ublituximab) and CD19 (inebilizumab), and molecules necessary for B-cell activation such as B cell activating factor (BAFF) (belimumab) and Bruton's Tyrosine Kinase (BTK) (evobrutinib).", "label": "yes"}
{"id": "63eef4f5f36125a42600000b_3", "question": "What disease is treated with Ublituximab?", "context": "Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.", "label": "yes"}
{"id": "63eef4f5f36125a42600000b_4", "question": "What disease is treated with Ublituximab?", "context": "Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis.", "label": "yes"}
{"id": "63eef4f5f36125a42600000b_5", "question": "What disease is treated with Ublituximab?", "context": "CONCLUSIONS: Among participants with relapsing multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not result in a significantly lower risk of worsening of disability. ", "label": "yes"}
{"id": "63eef4f5f36125a42600000b_6", "question": "What disease is treated with Ublituximab?", "context": "The glycoengineered antibody ublituximab is the next anti-CD20 therapy about to be approved. ", "label": "yes"}
{"id": "63eef4f5f36125a42600000b_7", "question": "What disease is treated with Ublituximab?", "context": "On the other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations. ", "label": "yes"}
{"id": "640c842f201352f04a000025_0", "question": "What is Palmar Erythema?", "context": "Palmar erythema (\"liver palms\") was seen in 32/100 consecutive patients with classical rheumatoid arthritis and in 10/100 patients with various other internal diseases (p less than 0.001", "label": "yes"}
{"id": "64468b0757b1c7a315000070_0", "question": "What is the cause of Oculopharyngeal Muscular Dystrophy (OPMD)?", "context": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness. It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the polyadenosine (poly[A]) binding protein nuclear 1 gene (11-18 repeats in OPMD instead of the normal 10 repeats).", "label": "yes"}
{"id": "64468b0757b1c7a315000070_1", "question": "What is the cause of Oculopharyngeal Muscular Dystrophy (OPMD)?", "context": "A common cause of OPMD is the short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene.", "label": "yes"}
{"id": "63f0494cf36125a426000028_0", "question": "Which viral disease can be treated with EDP-938?", "context": "EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.", "label": "yes"}
{"id": "63f0494cf36125a426000028_1", "question": "Which viral disease can be treated with EDP-938?", "context": "EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein.", "label": "yes"}
{"id": "63f0494cf36125a426000028_2", "question": "Which viral disease can be treated with EDP-938?", "context": "EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus.", "label": "yes"}
{"id": "63f0494cf36125a426000028_3", "question": "Which viral disease can be treated with EDP-938?", "context": "EDP-938 has shown high efficacy against RSV. ", "label": "yes"}
{"id": "63f0494cf36125a426000028_4", "question": "Which viral disease can be treated with EDP-938?", "context": "EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model.", "label": "yes"}
{"id": "63f0494cf36125a426000028_5", "question": "Which viral disease can be treated with EDP-938?", "context": "EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). ", "label": "yes"}
{"id": "640ddbe9201352f04a000027_0", "question": "What is the generic name for Imfinzi?", "context": "durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),", "label": "yes"}
{"id": "640ddbe9201352f04a000027_1", "question": "What is the generic name for Imfinzi?", "context": "durvalumab (IMFINZI\u00ae, Astra-Zeneca", "label": "yes"}
{"id": "640ddbe9201352f04a000027_2", "question": "What is the generic name for Imfinzi?", "context": "durvalumab (Imfinzi\u00ae)", "label": "yes"}
{"id": "644e81fa57b1c7a315000079_0", "question": "What are negative cell-cycle regulators that can cause cancer when mutated called?", "context": "The cell cycle (or cell-division cycle) is a series of events that take place in a cell, leading to its division and duplication. Cell division requires cell cycle checkpoints (CPs) that are used by the cell to both monitor and regulate the progress of the cell cycle. Tumor-suppressor genes (TSGs) or antioncogenes are genes that protect the cell from a single event or multiple events leading to cancer. When these genes mutate, the cell can progress to a cancerous state.", "label": "yes"}
{"id": "644e81fa57b1c7a315000079_1", "question": "What are negative cell-cycle regulators that can cause cancer when mutated called?", "context": "Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation.", "label": "yes"}
{"id": "644e81fa57b1c7a315000079_2", "question": "What are negative cell-cycle regulators that can cause cancer when mutated called?", "context": " We now recognize that tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses, detection and repair of DNA damage, protein ubiquitination and degradation, mitogenic signaling, cell specification, differentiation and migration, and tumor angiogenesis.", "label": "yes"}
{"id": "6415c7fb690f196b51000016_0", "question": "When was Keytruda approved for the treatment of melanoma?", "context": "On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. ", "label": "yes"}
{"id": "64468e0d57b1c7a315000071_0", "question": "What is the incidence of Oculopharyngeal Muscular Dystrophy (OPMD)?", "context": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset rare muscle disease affecting approximately 1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals in some populations due to a strong founder effect. ", "label": "yes"}
{"id": "63f04716f36125a426000025_0", "question": "Donidalorsen was tested for which disease?", "context": "BACKGROUND: Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal. Selective inhibition of plasma prekallikrein production by antisense oligonucleotide treatment (donidalorsen) may reduce the frequency of attacks and the burden of disease.", "label": "yes"}
{"id": "63f04716f36125a426000025_1", "question": "Donidalorsen was tested for which disease?", "context": "CONCLUSIONS: Among patients with hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial.", "label": "yes"}
{"id": "63f04716f36125a426000025_2", "question": "Donidalorsen was tested for which disease?", "context": "Investigational therapies, including the activated factor XII inhibitor garadacimab and an antisense oligonucleotide targeting plasma prekallikrein messenger RNA (donidalorsen), have shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE, further research is needed to determine how best to individualize optimal treatments for each patient.", "label": "yes"}
{"id": "644ec7fe57b1c7a315000082_0", "question": "What are the proteins that are necessary for the use of lactose in E. coli collectively called?", "context": "The lac operon is one of the best known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions. It is nearly ubiquitous in Escherichia coli strains justifying the use of its phenotype, the ability to consume lactose, for species identification.", "label": "yes"}
{"id": "644ec7fe57b1c7a315000082_1", "question": "What are the proteins that are necessary for the use of lactose in E. coli collectively called?", "context": "Transcription of bacterial genes is controlled by the coordinated action of cis- and trans-acting regulators. The activity and mode of action of these regulators can reflect different requirements for gene products in different environments. A well-studied example is the regulatory function that integrates the environmental availability of glucose and lactose to control the Escherichia colilac operon. Most studies of lac operon regulation have focused on a few closely related strains.", "label": "yes"}
{"id": "63fa16d8201352f04a000002_0", "question": "Alternative microexon splicing is associated with metastasis in which cancer?", "context": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.", "label": "yes"}
{"id": "63fa16d8201352f04a000002_1", "question": "Alternative microexon splicing is associated with metastasis in which cancer?", "context": "Finally, we found that changes in the pattern of microexon splicing were associated with CRC metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.", "label": "yes"}
{"id": "6451060c57b1c7a315000096_0", "question": "What is the cause of spinal-bulbar muscular atrophy?", "context": "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene (AR).", "label": "yes"}
{"id": "6451060c57b1c7a315000096_1", "question": "What is the cause of spinal-bulbar muscular atrophy?", "context": "Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation in the androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons to cause SBMA.", "label": "yes"}
{"id": "6451060c57b1c7a315000096_2", "question": "What is the cause of spinal-bulbar muscular atrophy?", "context": "spinal and bulbar muscular atrophy (SBMA), an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene.", "label": "yes"}
{"id": "61f7c904882a024a10000027_0", "question": "Which disease can be treated using Tezepelumab?", "context": "SUMMARY: Clinical trials demonstrated that tezepelumab, an anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma that is effective also in nontype 2 asthma.", "label": "yes"}
{"id": "61f7c904882a024a10000027_1", "question": "Which disease can be treated using Tezepelumab?", "context": "Tezepelumab in adults and adolescents with severe, uncontrolled asthma. ", "label": "yes"}
{"id": "61f7c904882a024a10000027_2", "question": "Which disease can be treated using Tezepelumab?", "context": "In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.", "label": "yes"}
{"id": "61f7c904882a024a10000027_3", "question": "Which disease can be treated using Tezepelumab?", "context": "Tezepelumab and other anti-alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma.", "label": "yes"}
{"id": "61f7c904882a024a10000027_4", "question": "Which disease can be treated using Tezepelumab?", "context": "Omalizumab, dupilumab, and tezepelumab can directly modulate the ASM in asthma, by specifically blocking the interaction between IgE, IL-4, and TSLP, and their receptors are located on the surface of ASM cells. ", "label": "yes"}
{"id": "61f7c904882a024a10000027_5", "question": "Which disease can be treated using Tezepelumab?", "context": "AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from eosinophilic asthma, therefore, well-designed head-to-head trials are needed to compare the efficacy of those mAbs that directly target ASM contractility specifically against the AHR in severe asthma, namely omalizumab, dupilumab, and tezepelumab.", "label": "yes"}
{"id": "61f7c904882a024a10000027_6", "question": "Which disease can be treated using Tezepelumab?", "context": "Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma. ", "label": "yes"}
{"id": "61f7c904882a024a10000027_7", "question": "Which disease can be treated using Tezepelumab?", "context": "Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.", "label": "yes"}
{"id": "61f7c904882a024a10000027_8", "question": "Which disease can be treated using Tezepelumab?", "context": "These results support the selection of 210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma.", "label": "yes"}
{"id": "644ef78f57b1c7a315000084_0", "question": "Chromatin is tightly packed into what structure inside the nucleus?", "context": "Our genetic information is tightly packaged into a rather ingenious nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes. Formation of the nucleosome, which is the fundamental unit of chromatin, occurs via a stepwise process that is reversed to enable the disassembly of nucleosomes.", "label": "yes"}
{"id": "644ef78f57b1c7a315000084_1", "question": "Chromatin is tightly packed into what structure inside the nucleus?", "context": "DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.", "label": "yes"}
{"id": "644298cc57b1c7a315000062_0", "question": "What is the cause of Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2)?", "context": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.", "label": "yes"}
{"id": "644298cc57b1c7a315000062_1", "question": "What is the cause of Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2)?", "context": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.", "label": "yes"}
{"id": "6442933f57b1c7a315000060_0", "question": "What is the cause of Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1)?", "context": "There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable. In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4", "label": "yes"}
{"id": "6442933f57b1c7a315000060_1", "question": "What is the cause of Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1)?", "context": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.", "label": "yes"}
